Bobbie J Rimel (B J Rimel, Bobbie Rimel)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Topics

Endometrial Cancer

Health Promotion

Top Venues

Oncology and therapy

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy (2024)
Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy 12 (3) (2024)
Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy 12 (3) (2024)
Bobbie J Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M Schilder, Jean A Hurteau, Amanda Golembesky
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study. Oncology and therapy 12 (3) (2024)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Charles A Kunos, Nikeya Macioce, Sarah M Temkin
Current gaps and opportunities in screening, prevention, and treatment of cervical cancer. Cancer 128 (23) (2022)
Therica M Miller, Jenny Lester, Lorna Kwan, Megha D Tandel, Beth Y Karlan, Bobbie J Rimel
21 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study. JCO clinical cancer informatics 4 (2021)